Table 1.
No (%) | |
No of patients | 26 |
Median age, years (range) | 67 (52–79) |
Female sex | 9 (34.6) |
BMI, median (range) | 26.1 (21.3–−38.5) |
Smoking status | |
Former | 22 (84.6) |
Never | 4 (15.4) |
Pulmonary history* | |
No | 19 (73.1) |
Yes | 7 (26.9) |
Primary malignancy | |
NSCLC | 8 (30.8) |
Malignant melanoma | 4 (15.4) |
Renal cell carcinoma | 4 (15.4) |
Sarcoma | 2 (7.7) |
Head and neck squamous cell cancer | 2 (7.7) |
Bladder carcinoma | 1 (3.8) |
Colorectal carcinoma | 1 (3.8) |
Esophageal squamous cell cancer | 1 (3.8) |
Multiple myeloma | 1 (3.8) |
Prostate cancer | 1 (3.8) |
SCLC | 1 (3.8) |
Line of therapy | |
1 | 9 (34.6) |
2 | 9 (34.6) |
≥3 | 8 (30.8) |
Prior chest radiation | |
No | 17 (65.4) |
Yes | 9 (34.6) |
Causative checkpoint inhibitor agent | |
PD1 | 16 (61.5) |
PDL1 | 3 (11.5) |
CTLA4 | 1 (3.8) |
Combination | 6 (23.1) |
*Asthma, COPD, OSA, bronchiectasis, ILD, history of pneumonitis, pulmonary embolism, pleural effusion.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung diseas; NSCLC, non-small cell lung cancer; OSA, obstructive sleep apnea.